Astellas Pharma (4503 JP): Strategic Brands Shine in FY26 as Xtandi Peaks, FY27 Guidance Revealed
Astellas Pharma sees strong revenue and profit growth in FY26, driven by strategic brands and cost optimization. This momentum is expected to...
198 Views
Otsuka Holdings (4578 JP): Rexulti, Abilify Gain Further Traction in 1Q26, Guidance Reiterated
Otsuka Holdings saw 8% revenue growth in 1Q26 driven by Rexulti and Abilify. Sibeprenlimab next big draw. Transcend acquisition positive....
170 Views
Chugai Pharma (4519 JP): Hemlibra Drive 1Q26, 2026 Guidance Reiterated, Orforglipron Launched in US
Chugai Pharma reports 11.5% revenue increase as Hemlibra overseas sales up 26% YoY. 2026 guidance reiterated. FDA approval for Founday...
298 Views
The Week That Was in NorthAsia@Smartkarma
This is the third report of "The Week That Was in North Asia@Smartkarma". This is a collaborative report among Mio Kato, CFA, Sanghyun Park,...
445 Views
The Week That Was in NorthAsia@Smartkarma
This is the second report of "The Week That Was in North Asia@Smartkarma". This is a collaborative report among Travis Lundy, Mio Kato, CFA,...
433 Views